Skip to main content
. Author manuscript; available in PMC: 2012 Aug 27.
Published in final edited form as: Clin Cancer Res. 2008 Jul 1;14(13):4284–4291. doi: 10.1158/1078-0432.CCR-07-5226

Figure 5. Matrigel invasion assay of HNSCC cell lines treated with AZD0530 and/or gefitinib.

Figure 5

Figure 5

(A) 1483 and (B) PCI-37B cells were plated in Matrigel-coated invasion chamber at a density of 1 × 104 cells/well in serum-free DMEM containing DMSO, AZD0530 (1 µM), gefitinib (at IC50 value), or combination of AZD0530 and gefitinib (both at IC50 values). Lower wells contained DMEM with 10% FBS. After 48 hours of treatment at 37°C in a 5% CO2 incubator, the cells in the insert were removed by wiping gently with a cotton swab. Cells on the reverse side of the insert were fixed and stained with Hema 3 (Fisher Scientific) according to the manufacturer’s instructions. Invading cells in 4 representative fields each from 3 replicates were counted using light microscopy at 200× magnification. Cumulative data from at least 5 independent experiments for both cell lines are shown.